Associate Director, Clinical Quality Assurance and Auditing
Amylyx Pharmaceuticals
Summary
The Associate Director, Clinical Quality Assurance and Auditing is responsible for supporting the development and execution of clinical quality assurance activities and leading Good Clinical Practice (GCP) auditing activities across the organization's clinical development programs. This role provides both strategic and operational quality oversight to ensure compliance with applicable global regulations, ICH GCP guidelines, company policies, and industry standards.
Job description
The Opportunity
The Associate Director, Clinical Quality Assurance and Auditing is responsible for supporting the development and execution of clinical quality assurance activities and leading Good Clinical Practice (GCP) auditing activities across the organization's clinical development programs. This role provides both strategic and operational quality oversight to ensure compliance with applicable global regulations, ICH GCP guidelines, company policies, and industry standards.
The Associate Director serves as a key quality partner to Clinical Operations, Clinical Development, Data Management, Biostatistics, Statistical Programming, Pharmacovigilance, Regulatory Affairs, Medical Affairs, and external service providers. The individual will lead and conduct risk-based GCP audits, support regulatory inspection readiness, oversee quality investigations and corrective and preventive actions (CAPAs), and identify opportunities for continuous improvement.
Clinical Quality Assurance and Oversight
- Support the development and execution of the Clinical Quality Assurance strategy, including risk-based quality management activities and the annual audit schedule.
- Provide quality oversight across clinical development programs to ensure compliance with GCP, applicable regulations, company procedures, and industry standards.
- Partner with clinical and cross-functional teams to proactively identify, assess, and mitigate quality and compliance risks.
- Provide quality guidance and consultation throughout the clinical trial lifecycle, including study planning, conduct, closeout, and regulatory submissions.
- Support quality management reviews, including the development, monitoring, and reporting of quality metrics, trends, and emerging risks.
- Lead and contribute to continuous improvement initiatives that strengthen clinical quality processes, systems, and operational effectiveness.
- Promote a culture of quality, accountability, and inspection readiness across clinical development functions.
GCP Auditing and Compliance
- Plan, lead, conduct, and report independent, risk-based GCP audits in accordance with the established audit strategy, annual audit schedule, and applicable regulatory requirements.
- Perform and oversee audits and assessments across clinical development activities, including investigator site audits, clinical study and process audits, vendor and CRO audits, TMF audits, computerized systems assessments, clinical data integrity assessments, and pharmacovigilance interface audits.
- Evaluate clinical trial activities and supporting systems for compliance with ICH E6(R3) GCP guidelines, FDA regulations (21 CFR Parts 11, 50, 54, 56, and 312), EU Clinical Trials Regulation, local and regional regulatory requirements, and company SOPs, policies, and quality standards.
- Prepare comprehensive audit reports that clearly document observations, compliance gaps, potential risks, and recommended corrective actions.
- Assess the adequacy of CAPA plans resulting from audit findings and verify their implementation and effectiveness through appropriate follow-up activities.
- Ensure audit documentation, reports, and supporting records are maintained in accordance with internal procedures and applicable requirements.
Regulatory Inspection Readiness and Support
- Lead and support inspection readiness activities across clinical development programs, investigator sites, and external service providers.
- Partner with internal stakeholders to prepare for regulatory inspections and ensure appropriate documentation, processes, and systems are inspection-ready.
- Conduct inspection readiness assessments, mock inspections, and gap analyses to identify and address potential areas of regulatory concern.
- Support the preparation, coordination, and execution of regulatory inspections, including responses to inspection observations, findings, and commitments.
- Track and trend inspection observations and findings to identify systemic compliance risks and opportunities for improvement.
- Collaborate with cross-functional teams to ensure timely and effective remediation of inspection-related findings.
Quality Investigations, CAPA, and Continuous Improvement
- Review and approve quality events, including deviations and CAPAs, in accordance with established quality procedures.
- Lead or provide oversight for complex quality investigations, ensuring appropriate root cause analysis, documentation, and risk assessment.
- Evaluate proposed corrective and preventive actions for adequacy, timeliness, and effectiveness.
- Monitor quality metrics, audit findings, deviations, and CAPA trends to identify emerging compliance risks and recurring quality issues.
- Partner with functional leaders to implement sustainable improvements that address systemic quality concerns.
- Provide quality guidance and share best practices with internal stakeholders and external partners to strengthen compliance and promote continuous improvement.
Work Location and Conditions
Amylyx supports remote work opportunities within the United States. Applicants residing and/or working in Alaska and Hawaii are not being considered. The role requires travel to the corporate location in Cambridge, MA several times a year and attendance at other company-related events as necessary.
Requirements
- Bachelor's degree in Life Sciences, Nursing, Pharmacy, Biological Sciences, or a related field required
- Advanced degree (MS, PharmD, PhD, MPH, or equivalent) preferred
- Minimum of 8 years of experience within pharmaceutical, biotechnology, medical device, or CRO environments
- Minimum of 5 years of experience in Clinical Quality Assurance
- Direct, hands-on experience planning, conducting, and reporting GCP audits required
- Experience supporting regulatory inspections and clinical inspection readiness activities required
- Demonstrated experience leading complex quality investigations, root cause analyses, and CAPA programs
- Experience working across Phase I–IV clinical trials preferred
- Experience supporting global clinical development programs preferred
- Expert knowledge of ICH GCP guidelines and applicable global clinical trial regulations
- Strong understanding of FDA and European regulatory requirements
- Strong understanding of risk-based Quality Management principles
- Strong understanding of clinical trial processes, systems, and documentation
- Strong understanding of clinical data integrity requirements
- Strong understanding of quality investigations, root cause analysis, and CAPA effectiveness
- Excellent auditing, interviewing, analytical, and technical report-writing skills
- Strong risk assessment, problem-solving, and decision-making capabilities
- Demonstrated ability to influence, advise, and collaborate effectively with stakeholders across all organizational levels
- Exceptional communication, interpersonal, and leadership skills
- Ability to independently manage multiple priorities in a dynamic, fast-paced clinical development environment
- Strong attention to detail while maintaining a broader strategic and risk-based perspective
Benefits
- Performance-based bonuses
- Equity awards
- Comprehensive benefits package
Company overview
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, founded in 2013 by co-CEOs Josh Cohen and Justin Klee. The company specializes in developing novel therapies for neurodegenerative diseases with high unmet medical needs, with a particular focus on amyotrophic lateral sclerosis (ALS), Wolfram syndrome, and post-bariatric hypoglycemia. Amylyx's lead investigational therapy, AMX0035, received FDA approval for ALS treatment under the brand name RELYVRIO in September 2022. The company employs a rigorous scientific approach to target multiple pathological pathways in neurodegeneration, with additional pipeline candidates including avexitide for metabolic disorders and AMX0114, an antisense oligonucleotide targeting calpain-2 for ALS. With a team of 201-500 employees, Amylyx combines therapeutic development expertise with commercialization capabilities to address some of medicine's most challenging conditions.